Celldex

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celldex and other ETFs, options, and stocks.

About CLDX

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. 

CEO
Anthony S. Marucci
CEOAnthony S. Marucci
Employees
198
Employees198
Headquarters
Hampton, New Jersey
HeadquartersHampton, New Jersey
Founded
1983
Founded1983
Employees
198
Employees198

CLDX Key Statistics

Market cap
2.51B
Market cap2.51B
Price-Earnings ratio
-7.57
Price-Earnings ratio-7.57
Dividend yield
Dividend yield
Average volume
681.52K
Average volume681.52K
High today
$32.45
High today$32.45
Low today
$31.87
Low today$31.87
Open price
$32.45
Open price$32.45
Volume
59.27K
Volume59.27K
52 Week high
$35.79
52 Week high$35.79
52 Week low
$18.47
52 Week low$18.47

Stock Snapshot

With a market cap of 2.51B, Celldex(CLDX) trades at $32.04. The stock has a price-to-earnings ratio of -7.57.

During the trading session on 2026-05-12, Celldex(CLDX) shares reached a daily high of $32.45 and a low of $31.87. At a current price of $32.04, the stock is +0.5% higher than the low and still -1.3% under the high.

Trading volume for Celldex(CLDX) stock has reached 59.27K, versus its average volume of 681.52K.

The stock's 52-week range extends from a low of $18.47 to a high of $35.79.

The stock's 52-week range extends from a low of $18.47 to a high of $35.79.

CLDX News

Simply Wall St 21h
The Bull Case For Celldex Therapeutics Could Change Following Q1 Loss And Barzolvolimab Milestones

Celldex Therapeutics recently reported first-quarter 2026 results, with revenue falling to US$15,000 from US$695,000 a year earlier and net loss widening to US$...

The Bull Case For Celldex Therapeutics Could Change Following Q1 Loss And Barzolvolimab Milestones
Simply Wall St 4d
Weighing Celldex Therapeutics Valuation As Price-To-Book And DCF Send Mixed Signals

Advertisement Celldex Therapeutics (CLDX) stock snapshot Celldex Therapeutics (CLDX) has drawn fresh attention after recent trading moves, with the stock show...

Weighing Celldex Therapeutics Valuation As Price-To-Book And DCF Send Mixed Signals
TipRanks 5d
Celldex reports Q1 EPS ($1.18), consensus ($1.13)

Reports Q1 revenue $15K, consensus $861K. Cash, cash equivalents and marketable securities as of March 31, were $451.5M compared to $518.6M as of December 31, 2...

Analyst ratings

93%

of 15 ratings
Buy
93.3%
Hold
6.7%
Sell
0%

People also own

Based on the portfolios of people who own CLDX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.